abiraterone has been researched along with finasteride in 4 studies
| Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) | Studies (finasteride) | Trials (finasteride) | Recent Studies (post-2010) (finasteride) |
|---|---|---|---|---|---|
| 942 | 97 | 854 | 2,514 | 405 | 867 |
| Protein | Taxonomy | abiraterone (IC50) | finasteride (IC50) |
|---|---|---|---|
| Cytochrome P450 2C9 | Homo sapiens (human) | 2 | |
| 3-oxo-5-alpha-steroid 4-dehydrogenase 1 | Homo sapiens (human) | 0.295 | |
| 3-oxo-5-alpha-steroid 4-dehydrogenase 1 | Rattus norvegicus (Norway rat) | 0.0109 | |
| 3-oxo-5-alpha-steroid 4-dehydrogenase 2 | Homo sapiens (human) | 0.0131 | |
| 3-oxo-5-alpha-steroid 4-dehydrogenase 2 | Rattus norvegicus (Norway rat) | 0.3286 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brodie, AM; Chopra, P; Farquhar, R; Gediya, LK; Guo, Z; Handratta, VD; Kataria, R; Newman, D; Njar, VC; Qiu, Y; Vasaitis, TS | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bini, V; Bortolato, M; Devoto, P; Frau, R; Pes, R; Pillolla, G; Saba, P | 1 |
| Boukovala, M; Brössner, C; Efstathiou, E; Gustafsson, JA; Spetsieris, N; Wang, L; Warner, M; Wu, WF | 1 |
4 other study(ies) available for abiraterone and finasteride
| Article | Year |
|---|---|
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstadienes; Animals; Antineoplastic Agents; Azoles; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Humans; Isoenzymes; Male; Mice; Mice, SCID; Mutation; Prostatic Neoplasms; Pyrazines; Radioligand Assay; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Tissue Distribution; Transcription, Genetic; Transcriptional Activation; Xenograft Model Antitumor Assays | 2005 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Inhibition of 17α-hydroxylase/C17,20 lyase reduces gating deficits consequent to dopaminergic activation.
Topics: 5-alpha Reductase Inhibitors; Androstenes; Androstenols; Animals; Apomorphine; Dopamine Agonists; Finasteride; Male; Rats; Rats, Sprague-Dawley; Reflex, Startle; Sensory Gating; Steroid 17-alpha-Hydroxylase | 2014 |
Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate.
Topics: Active Transport, Cell Nucleus; Androgen Antagonists; Androstenes; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Cell Nucleus; Cohort Studies; ErbB Receptors; Estrogen Receptor beta; Finasteride; Humans; Male; Mice; Mice, Knockout; Neoplasm Grading; Nitriles; Phenylthiohydantoin; Phytoestrogens; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Androgen; Receptors, Estrogen | 2021 |